Related references
Note: Only part of the references are listed.Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results
Jenny Link et al.
PLOS ONE (2017)
Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta
Christina Hermanrud et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2016)
The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy
Damiano Paolicelli et al.
PLOS ONE (2016)
Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis
Delphine Bachelet et al.
PLOS ONE (2016)
Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium
B. Rup et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2015)
Antibody dissociation rates are predictive of neutralizing antibody (NAb) course: A comparison of interferon beta-1b-treated Multiple Sclerosis (MS) patients with transient versus sustained NAbs
Ebrima Gibbs et al.
CLINICAL IMMUNOLOGY (2015)
PML: The Dark Side of Immunotherapy in Multiple Sclerosis
Clemens Warnke et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
Human Leukocyte Antigen Genes and Interferon Beta Preparations Influence Risk of Developing Neutralizing Anti-Drug Antibodies in Multiple Sclerosis
Jenny Link et al.
PLOS ONE (2014)
Socio-economic aspects of the testing for antibodies in MS-patients under interferon therapy in Austria: A cost of illness study
Evelyn Walter et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2014)
Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards
Clemens Warnke et al.
JOURNAL OF NEURAL TRANSMISSION (2013)
Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies
Hans-Peter Hartung et al.
JOURNAL OF NEUROINFLAMMATION (2012)
Influence of the HLA-DRB1 Genotype on Antibody Development to Interferon Beta in Multiple Sclerosis
Dorothea Buck et al.
ARCHIVES OF NEUROLOGY (2011)
Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics
Shalini Gupta et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2011)
Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome
H. -P. Hartung et al.
NEUROLOGY (2011)
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis
Chris H. Polman et al.
LANCET NEUROLOGY (2010)
Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid are less likely to develop neutralizing antibodies against interferon beta
M. Lundkvist et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
HLA-DRBI*0401 and HLA-DRBI*0408 are strongly associated with the development of antibodies against interferon-β therapy in multiple sclerosis
Steve Hoffmann et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2008)
Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products
Gopi Shankar et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2008)
Immunogenicity of protein therapeutics
Anne S. De Groot et al.
TRENDS IN IMMUNOLOGY (2007)
A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs
Gopi Shankar et al.
NATURE BIOTECHNOLOGY (2007)
Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics
Shalini Gupta et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2007)
Neutralizing antibodies and efficacy of interferon β-1a -: A 4-year controlled study
L Kappos et al.
NEUROLOGY (2005)
Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products
AR Mire-Sluis et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2004)
Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b
C Polman et al.
NEUROLOGY (2003)
Share Paper
